49.96
0.77 (1.57%)
| Previous Close | 49.19 |
| Open | 49.25 |
| Volume | 1,162,475 |
| Avg. Volume (3M) | 1,345,314 |
| Market Cap | 5,739,559,424 |
| Price / Sales | 13.14 |
| Price / Book | 23.39 |
| 52 Weeks Range | |
| Earnings Date | 14 May 2026 |
| Diluted EPS (TTM) | -2.55 |
| Total Debt/Equity (MRQ) | 20.22% |
| Current Ratio (MRQ) | 10.25 |
| Operating Cash Flow (TTM) | -229.84 M |
| Levered Free Cash Flow (TTM) | -134.32 M |
| Return on Assets (TTM) | -50.15% |
| Return on Equity (TTM) | -106.71% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Scholar Rock Holding Corporatio | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 4.0 |
| Average | 1.88 |
|
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 4.35% |
| % Held by Institutions | 118.63% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Samsara Biocapital, Llc | 31 Dec 2025 | 6,897,652 |
| Paradigm Biocapital Advisors Lp | 31 Dec 2025 | 3,062,157 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 70.00 (BMO Capital, 40.11%) | Buy |
| Median | 58.00 (16.09%) | |
| Low | 53.00 (Barclays, 6.09%) | Buy |
| Average | 58.67 (17.43%) | |
| Total | 6 Buy | |
| Avg. Price @ Call | 46.91 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| BMO Capital | 04 Mar 2026 | 70.00 (40.11%) | Buy | 47.43 |
| Barclays | 04 Mar 2026 | 53.00 (6.08%) | Buy | 47.43 |
| Citigroup | 04 Mar 2026 | 58.00 (16.09%) | Buy | 47.43 |
| Piper Sandler | 04 Mar 2026 | 58.00 (16.09%) | Buy | 47.43 |
| Truist Securities | 04 Mar 2026 | 55.00 (10.09%) | Buy | 47.43 |
| HC Wainwright & Co. | 03 Mar 2026 | 58.00 (16.09%) | Buy | 44.31 |
| 26 Jan 2026 | 58.00 (16.09%) | Buy | 44.89 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 16 Jan 2026 | Announcement | Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |